TY - JOUR
T1 - Safeguarding female reproductive health against endocrine disrupting chemicals—The FREIA project
AU - van Duursen, Majorie B.M.
AU - Boberg, Julie
AU - Christiansen, Sofie
AU - Connolly, Lisa
AU - Damdimopoulou, Pauliina
AU - Filis, Panagiotis
AU - Fowler, Paul A.
AU - Gadella, Bart M.
AU - Holte, Jan
AU - Jääger, Kersti
AU - Johansson, Hanna K.L.
AU - Li, Tianyi
AU - Mazaud-Guittot, Séverine
AU - Parent, Anne Simone
AU - Salumets, Andres
AU - Soto, Ana M.
AU - Svingen, Terje
AU - Velthut-Meikas, Agne
AU - Wedebye, Eva Bay
AU - Xie, Yuling
AU - van den Berg, Martin
PY - 2020/5/2
Y1 - 2020/5/2
N2 - Currently available test methods are not well-suited for the identification of chemicals that disturb hormonal processes involved in female reproductive development and function. This renders women’s reproductive health at increasing risk globally, which, coupled with increasing incidence rates of reproductive disorders, is of great concern. A woman’s reproductive health is largely established during embryonic and fetal development and subsequently matures during puberty. The endocrine system influences development, maturation, and function of the female reproductive system, thereby making appropriate hormone levels imperative for correct functioning of reproductive processes. It is concerning that the effects of human-made chemicals on the endocrine system and female reproductive health are poorly addressed in regulatory chemical safety assessment, partly because adequate test methods are lacking. Our EU-funded project FREIA aims to address this need by increasing understanding of how endocrine disrupting chemicals (EDCs) can impact female reproductive health. We will use this information to provide better test methods that enable fit-for-purpose chemical regulation and then share our knowledge, promote a sustainable society, and improve the reproductive health of women globally.
AB - Currently available test methods are not well-suited for the identification of chemicals that disturb hormonal processes involved in female reproductive development and function. This renders women’s reproductive health at increasing risk globally, which, coupled with increasing incidence rates of reproductive disorders, is of great concern. A woman’s reproductive health is largely established during embryonic and fetal development and subsequently matures during puberty. The endocrine system influences development, maturation, and function of the female reproductive system, thereby making appropriate hormone levels imperative for correct functioning of reproductive processes. It is concerning that the effects of human-made chemicals on the endocrine system and female reproductive health are poorly addressed in regulatory chemical safety assessment, partly because adequate test methods are lacking. Our EU-funded project FREIA aims to address this need by increasing understanding of how endocrine disrupting chemicals (EDCs) can impact female reproductive health. We will use this information to provide better test methods that enable fit-for-purpose chemical regulation and then share our knowledge, promote a sustainable society, and improve the reproductive health of women globally.
KW - Adrenal
KW - Bioassay
KW - Endocrine disrupting chemicals
KW - Female reproductive health
KW - Fertility
KW - Mammary gland
KW - Oocyte
KW - Ovary
KW - Risk assessment
KW - Steroidogenesis
KW - Test methods
UR - https://www.mendeley.com/catalogue/460fef04-b578-3e56-ac5e-97333a51903a/
U2 - 10.3390/ijms21093215
DO - 10.3390/ijms21093215
M3 - Article
C2 - 32370092
SN - 1661-6596
VL - 21
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 9
M1 - 3215
ER -